<DOC>
	<DOCNO>NCT00117442</DOCNO>
	<brief_summary>The purpose study provide dose-finding information regard efficacy kinetics peripheral blood progenitor cell ( PBPC ) mobilisation pegfilgrastim determine carboplatin/paclitaxel deliver reduced cycle interval support pegfilgrastim-mobilised PBPCs whole blood .</brief_summary>
	<brief_title>A Study Carboplatin/Paclitaxel With Pegfilgrastim Supported Haematopoietic Progenitor Cell Re-Infusion Whole Blood</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Pathologically confirm diagnosis malignancy ( solid tumour ) suitable treatment intensify carboplatin paclitaxel Previously untreated chemotherapy radiotherapy ECOG performance status 0 2 inclusive Life expectancy great equal 12 week ANC great equal 2.0 x 10^9/L , platelet great 100 x 10^9/L Glomerular filtration rate great 60 mL/min Active infection require treatment systemic ( IV oral ) antiinfectives ( antibiotic , antifungal , antiviral ) within 72 hour randomisation Known HIV positive Any premalignant myeloid condition malignancy myeloid characteristic ( e.g. , myelodysplastic syndrome , acute chronic myelogenous leukaemia ) Prior malignancy within last 5 year , exception surgically cure basal/squamous skin cell carcinoma , and/or carcinoma cervix insitu History impair cardiac status [ e.g. , severe heart disease ( NYHA great 2 ) , cardiomyopathy , congestive heart failure ] Bone marrow involvement disease Major surgery within 2 week randomisation Known sensitivity E. coli derive drug product ( e.g. , filgrastim ) Previous exposure pegfilgrastim</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>solid tumour</keyword>
	<keyword>unknown primary tumour</keyword>
	<keyword>carboplatin</keyword>
	<keyword>paclitaxel</keyword>
</DOC>